A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer

BACKGROUND: Panitumumab+best supportive care (BSC) significantly improved progression-free survival (PFS) vs BSC alone in patients with chemo-refractory wild-type KRAS metastatic colorectal cancer (mCRC). We applied the quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, J, Zhao, Z, Barber, B, Sherrill, B, Peeters, M, Wiezorek, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111208/
https://www.ncbi.nlm.nih.gov/pubmed/21610704
http://dx.doi.org/10.1038/bjc.2011.179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111208/
https://www.ncbi.nlm.nih.gov/pubmed/21610704
http://dx.doi.org/10.1038/bjc.2011.179

Ejemplares similares